Oxford Endovascular funding news – Oxford University Spinout Oxford Endovascular Raises £8Million in Series A Round Funding

The medtech startup, which was established in 2015, aspires to mitigate the incidence of cerebral haemorrhage by treating intracranial aneurysms. OXIFLOW, their device, redirects blood flow from intracranial aneurysms that are susceptible to rupture. In order to advance towards clinical studies, the capital raised will be utilised to fund additional product development.

Read also - PIXEVIA funding news – Retailtech Startup PIXEVIA Secures €1.5 Million in Funding

OXIFLOW is a flow-diverter catheter that is employed to treat intracranial aneurysms that are at risk of rupture. The Nitinol, an advanced nickel titanium alloy with superior memory and design capabilities, is used to laser-cut the miniature device.

OXIFLOW's construction enables it to position and open with greater accuracy and reliability than conventional flow-diverters, as per the outset. It is intended to adapt to the patient's blood vessels and mitigate the risk of complications that are associated with current treatments. Complications that may result in adverse events may occur in up to 35% of the current device placements used to treat cerebral aneurysms.

CEO Mike Karim said: “With the support of our investment partners, we are close to realising our vision of transforming brain aneurysm treatment. As we approach First-In-Human trials, our expert team is focused on working with regulators, physicians, and industry experts to bring this product to market and help tackle a condition that afflicts so many in the UK and worldwide.”

Oxford Endovascular has also received financial support in the form of grants from Horizon Europe, the EU's main funding programme for research and innovation, and Innovate UK, the UK's national innovation agency. Additionally, the EU has selected Oxford Endovascular for its EIT-funded Covid rescue programme.

About Oxford Endovascular Ltd

Oxford Endovascular Ltd is a spin-out from Oxford University that is dedicated to the prevention of brain haemorrhage through the treatment of brain aneurysms, a condition that effects 1 in 50 individuals.

Introducing OxiFlow™️, a cutting-edge, next-generation flow diverter that redirects blood flow from intracranial aneurysms that are at risk of rupture. It reduces the risk of complications by placing more accurately and safely than existing devices.